Why the study?
Does intratracheal transfer of the eNOS gene reduce pulmonary vascular resistance and attenuate pulmonary hypertension in mice?
Population
Mice, including a model exposed to the fibrogenic anticancer agent bleomycin to induce pulmonary hypertension
Comparison
Intratracheal administration of adenoviral… vs Control mice
Design
Preclinical
Follow-up
Up to 21-28 days
Authors
Loading...
Hypothesis-generating for lung-targeted eNOS gene therapy in pulmonary hypertension; human trials needed before any clinical consideration.
Does intratracheal transfer of the eNOS gene reduce pulmonary vascular resistance and attenuate pulmonary hypertension in mice?
In vivo gene transfer of eNOS to the lung selectively reduces pulmonary vascular resistance and attenuates bleomycin-induced pulmonary hypertension in mice, suggesting a potential therapeutic approach for pulmonary hypertensive disorders.
Champion et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: